Analysis of correlation between the EBV-DNA, SAA, and outcomes
EBV-negative
EBV-DNA was detected after first-line chemotherapy in 51.9% (95/183) of all participants. The participants who received S1 MT had better PFS and OS. Indeed, the median PFS and OS in the EBV-DNA-positive and EBV-negative participants in the S1-MT group and the EBV-DNA-positive and EBV-negative participants in the non-MT group were 18.5, 15.2, 7.5, and 10.5 months (Comparison of progression-free survival (PFS) and overall survival (OS) Kaplan–Meier survival curves of patients with different EBV-DNA status (In total, 46.4% (85/183) of patients during first-line treatment had a continuous decrease in SAA levels. The median PFS and OS of the participants with continuously decreased vs. stable SAA in the S1-MT group, and those with continuously decreased vs. stable SAA in the non-MT group were 17.1 vs. 15.2 and 4.5 vs. 10.2 months (